Get Adobe Flash player
Why Innovation?
Creating an environment that fosters innovation is a prerequisite to having a competitive business climate and economic growth. Being innovation-friendly attracts research and investment; provides incentive to expand or relocate; creates jobs and ultimately leads to new cures, technologies and products to improve our quality of life.
Innovation Time Line
Below is a timeline of innovation advancement. Click on the page for a larger view.
Member Profiles

HINJ Op-Ed: The Value of Medical Innovation: Saving Lives, Saving Money

New Brunswick, NJ, December 18, 2014 HealthCare Institute of New Jersey (HINJ) President and Chief Executive Officer Dean J. Paranicas has authored the following op-ed on the life sciences and the value of medical innovation.

*     *     *

Medical innovations produced by American life sciences companies have vastly improved the human condition.  Our pharmaceutical, biotech, medical technology, device and diagnostics companies have helped people live longer, with less pain and greater quality of life.

Over the past century, the life sciences has eradicated some of the world’s most dreaded diseases such as polio and smallpox.  More recently, the industry has made other diseases such as breast cancer, HIV/AIDS, heart disease and lung cancer no longer the death sentences that they once were.

Collectively, new therapies are the greatest contributors to increased life expectancy.  According to the National Bureau of Economic Research (NBER), between 1960 and 1997, new therapies accounted for 45 percent of the increase in life expectancy in 30 developing and high-income countries.  Between 2000 and 2009, new therapies accounted for 73 percent of the increased life expectancy for these countries.

Despite the dramatic life-saving advancements that the life sciences sector has made, our work is far from done. Read the rest of this entry »

NIA coordinating center for Alzheimer’s research

This Funding Opportunity Announcement (FOA) invites applications to establish an NIA Coordination Center to facilitate and support the Replication Phase of the Alzheimer’s Disease (AD) Sequencing Project (ADSP) activities. The Coordinating Center for the Genetics and Genomics of Alzheimer’s Disease (CGAD) will serve as the focal point for ADSP replication phase joint data analysis, harmonization, and sharing. The FOA is intended to support a major component of the full range of analysis for the Replication Phase of the ADSP.

For more information, click here.

NJ Congressman continues to lead Rare Disease Caucus

Washington, D.C., December 16. 2014 - Congressman Leonard Lance (NJ-07) will continue to co-chair the Congressional Rare Disease Caucus in the 114th Congress that will begin in January. Led by Rep. Lance and Congressman Joe Crowley (NY-14), the Congressional Rare Disease Caucus is a forum for Members of Congress to voice constituent concerns, collaborate on ideas, facilitate conversations between the medical and patient community and build support for legislation that will improve the lives of people with rare diseases. Read the rest of this entry »

Jersey City wins $2.3million Bloomberg grant to fund innovation team

Jersey City, NJ, December 16, 2014 - Jersey City was one of 14 cities that received an innovation grant from the Mike Bloomberg's philanthropic foundation. The City received $2.25 million to create a data-drive innovation team, or "i-team," that will focus on violent crime, youth development and economic development. Fourteen cities ranging from Long Beach, California, to Jerusalem, the Bloomberg Philanthropies grants range from $400,000 to $1 million annually for three years, expanding and internationalizing awards to five U.S. cities in 2011. The teams are styled as in-house innovation consultants who work on a series of mayoral priorities. Read the rest of this entry »
Calendar of Events
Innovation Daily
Selected innovation related articles from around the world on a daily basis.
Innovation NJ in Action